Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
25-2
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
25-2
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #30330
advertisement
Bacharach J
15
Showing records 1 to 15 |
Display all abstracts from
Bacharach J
125320
Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: ANGEL-2
Wirta DL
Ophthalmology. Glaucoma
2025; 0:
126658
Negative Pressure Application by the Ocular Pressure Adjusting Pump to Lower Intraocular Pressure in Normal-Tension Glaucoma: HERCULES Study
Ferguson TJ
American Journal of Ophthalmology
2025; 275: 121-134
125399
Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
Bacharach J
Clinical Ophthalmology
2025; 19: 175-186
126658
Negative Pressure Application by the Ocular Pressure Adjusting Pump to Lower Intraocular Pressure in Normal-Tension Glaucoma: HERCULES Study
Samuelson TW
American Journal of Ophthalmology
2025; 275: 121-134
125399
Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
Sadri E
Clinical Ophthalmology
2025; 19: 175-186
125320
Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: ANGEL-2
El-Harazi SM
Ophthalmology. Glaucoma
2025; 0:
125399
Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
Sawhney G
Clinical Ophthalmology
2025; 19: 175-186
125320
Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: ANGEL-2
Tepedino ME
Ophthalmology. Glaucoma
2025; 0:
126658
Negative Pressure Application by the Ocular Pressure Adjusting Pump to Lower Intraocular Pressure in Normal-Tension Glaucoma: HERCULES Study
Herndon L
American Journal of Ophthalmology
2025; 275: 121-134
125320
Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: ANGEL-2
Bacharach J
Ophthalmology. Glaucoma
2025; 0:
126658
Negative Pressure Application by the Ocular Pressure Adjusting Pump to Lower Intraocular Pressure in Normal-Tension Glaucoma: HERCULES Study
Terveen DC
American Journal of Ophthalmology
2025; 275: 121-134
125399
Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
Kopczynski C
Clinical Ophthalmology
2025; 19: 175-186
126658
Negative Pressure Application by the Ocular Pressure Adjusting Pump to Lower Intraocular Pressure in Normal-Tension Glaucoma: HERCULES Study
Bacharach J
American Journal of Ophthalmology
2025; 275: 121-134
125399
Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
Merchea MM
Clinical Ophthalmology
2025; 19: 175-186
126658
Negative Pressure Application by the Ocular Pressure Adjusting Pump to Lower Intraocular Pressure in Normal-Tension Glaucoma: HERCULES Study
Brubaker JW; Berdahl JP; Radcliffe NM
American Journal of Ophthalmology
2025; 275: 121-134
Issue
25-2
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept